The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer: Apatinib in metastatic TNBC
Open accessAbstract
Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase II study aims to evaluate the optimum dose level for the efficacy and safety of apatinib monotherapy in heavily pretreated patients with metastatic triple negative breast cancer (mTNBC) in China. Phase IIa was first performed among 25 patients previously treated with anthracycline and/or taxane. All patients received apatinib 750 mg/day p.o. in a 4-week cycle. Subsequently, a phase IIb study of 59 patients was activated, with the endpoint progression-free survival (PFS). The dosage of drug for the Phase IIb was determined according to safety, tolerability and efficacy from the phase IIa study. As a result of toxicity associated with the 750 mg dose in phase IIa, the recommended initial dose of apatinib in the phase IIb was 500 mg/day. In phase IIb, grade 3/4 hematologic toxicities were thrombocytopenia (13.6%), leukopenia (6.8%), neutropenia (3.4%) and anemia (1.7%). The most frequent grade 3/4 nonhematologic toxicities were hand-foot syndrome, proteinuria, hypertension, and increased ALT. In the 56 evaluable patients, overall response rate and clinical benefit rate (CBR) were 10.7 and 25.0%, respectively. Median PFS and overall survival were 3.3 (95% CI 1.7-5.0) and 10.6 (95% CI 5.6-15.7) months, respectively. Our results indicate that apatinib dose of 500 mg rather than 750 mg is the recommended starting dose for the heavily pretreated mTNBC patients with measurable rate of partial response and PFS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Molecular Stratification of Triple-Negative Breast Cancers
Perou, C. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-61 · Cited by 582
Li, J., Qin, S., Xu, J., Guo, W., Xiong, J., Bai, Y., Sun, G., Yang, Y., Wang, L., Xu, N., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.8585 · Cited by 533
Self-citationCooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
Wedam, S. B., Low, J. A., Yang, S. X., Chow, C. K., Choyke, P., Danforth, D., Hewitt, S. M., Berman, A., Steinberg, S. M., Liewehr, D. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4645 · Cited by 518
Tian, S., Quan, H., Xie, C., Guo, H., Lü, F., Xu, Y., Li, J., & Lou, L. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01939.x · Cited by 513
Self-citationBurstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., Lehman, M., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489
Zhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9908 · Cited by 477
Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., Fralick, M., Kumar, R., & Clemons, M. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.005 · Cited by 474
Mi, Y.-J., Liang, Y.-J., Huang, H.-B., Zhao, H.-Y., Wu, C.-P., Wang, F., Tao, L.-Y., Zhang, C.-Z., Dai, C.-L., Tiwari, A. K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0111 · Cited by 337
DePrimo, S. E., Bello, C. L., Smeraglia, J., Baum, C. M., Spinella, D., Rini, B. I., Michaelson, M. D., & Motzer, R. J. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-32 · Cited by 318
Gray, R., Bhattacharya, S., Bowden, C., Miller, K., & Comis, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6630 · Cited by 294
Li, J., Zhao, X., Chen, L., Guo, H., Lv, F., Jia, K., Yv, K., Wang, F., Li, C., Qian, J., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-529 · Cited by 265
Self-citationBergh, J., Bondarenko, I. M., Lichinitser, M. R., Liljegren, A., Greil, R., Voytko, N. L., Makhson, A. N., Cortes, J., Lortholary, A., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.7376 · Cited by 264
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
Murukesh, N., Dive, C., & Jayson, G. C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605483 · Cited by 237
DNA Mismatch Repair Gene Polymorphisms Affect Survival in Pancreatic Cancer
Dong, X., Li, Y., Hess, K. R., Abbruzzese, J. L., & Li, D. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0127 · Cited by 216
Barrios, C. H., Liu, M.-C., Lee, S. C., Vanlemmens, L., Ferrero, J.-M., Tabei, T., Pivot, X., Iwata, H., Aogi, K., Lugo-Quintana, R., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0788-0 · Cited by 199
Survivin Expression Quantified by Image Pro-plus Compared With Visual Assessment
Wang, C.-J., Zhou, Z.-G., Holmqvist, A., Zhang, H., Li, Y., Adell, G., & Sun, X.-F. (2009) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0b013e3181a13bf2 · Cited by 172
Baselga, J., Segalla, J. G. M., Roché, H., del Giglio, A., Pinczowski, H., Ciruelos, E. M., Filho, S. C., Gómez, P., Van Eyll, B., Bermejo, B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7771 · Cited by 164
Brufsky, A., Valero, V., Tiangco, B., Dakhil, S. R., Brize, A., Rugo, H. S., Rivera, R., Duenne, A., Bousfoul, N., & Yardley, D. A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2008-6 · Cited by 137
Weigand, M., Hantel, P., Kreienberg, R., & Waltenberger, J. L. (2005) · Angiogenesis · doi:10.1007/s10456-005-9010-0 · Cited by 135
Jonasch, E. W., Corn, P. G., Pagliaro, L. C., Warneke, C. L., Johnson, M. M., Tamboli, P., Ng, C. S., Aparicio, A. M., Ashe, R. G., Wright, J. J., et al. (2009) · Cancer · doi:10.1002/cncr.24685 · Cited by 120
Machado, D. E., Berardo, P. T., Palmero, C. Y., & Nasciutti, L. E. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-4 · Cited by 120
Tong, X.-Z., Wang, F., Liang, S.-L., Zhang, X., He, J., Chen, X.-G., Liang, Y.-J., Mi, Y., To, K. K. W., & Fu, L. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.007 · Cited by 119
Robert, N. J., Saleh, M. N., Paul, D., et al. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.03.005 · Cited by 119
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
Bianchi, G., Loibl, S., Zamagni, C., Salvagni, S., Raab, G., Siena, S., Laferriere, N., Peña, C. E., Lathia, C. D., Bergamini, L., et al. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832b2ea0 · Cited by 116
T1N0 Triple Negative Breast Cancer: Risk of Recurrence and Adjuvant Chemotherapy
Kaplan, H. G., Malmgren, J. A., & Atwood, M. K. (2009) · The Breast Journal · doi:10.1111/j.1524-4741.2009.00789.x · Cited by 88
Chung, A. S., Kowanetz, M., Wu, X., Zhuang, G., Ngu, H., Finkle, D., Kömüves, L. G., Peale, F. V., Jr., & Ferrara, N. (2012) · The Journal of Pathology · doi:10.1002/path.4052 · Cited by 88
Hanrahan, E. O., Ryan, A. J., Mann, H., Kennedy, S. J., Langmuir, P. B., Natale, R. B., Herbst, R. S., Johnson, B. E., & Heymach, J. V. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2568 · Cited by 88
Schwartzberg, L. S., Tauer, K. W., Hermann, R. C., Makari‐Judson, G., Isaacs, C. J., Beck, J. T., Kaklamani, V., Stepanski, E. J., Rugo, H. S., Wang, W., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3177 · Cited by 74
Kelly, R. J., Rajan, A., Force, J. M., López-Chávez, A., Keen, C., Cao, L., Yu, Y., Choyke, P. L., Türkbey, B., Raffeld, M. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2331 · Cited by 70
Contrasting effects of sunitinib within in vivo models of metastasis
Welti, J. C., Powles, T. B., Foo, S., Gourlaouen, M., Preece, N., Foster, J., Frentzas, S., Bird, D., Sharpe, K., van Weverwijk, A., et al. (2012) · Angiogenesis · doi:10.1007/s10456-012-9291-z · Cited by 69
Crown, J. P., Dieras, V. C., Starosławska, E., Yardley, D. A., Davidson, N. G. P., Bachelot, T., Tassell, V. R., Huang, X., Kern, K. A., & Romieu, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.18_suppl.lba1011 · Cited by 68
Fox, S. B., Turley, H., Cheale, M., Blázquez, C., Roberts, H., James, N. H., Cook, N., Harris, A. L., & Gatter, K. C. (2004) · The Journal of Pathology · doi:10.1002/path.1520 · Cited by 55
Rugo, H. S., Roche, H. H., Thomas, E., Blackwell, K., Chung, H., Lerzo, G. L., Volles, L., Poulart, V., & Perez, E. A. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-3057 · Cited by 46
Li, D., Chiu, H., Gupta, V., & Chan, D. W. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.06.017 · Cited by 27
Phase II open-label study of sunitinib in patients with advanced breast cancer
Yardley, D. A., Dees, E. C., Myers, S., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2285-0 · Cited by 23
Cited by
Jiang, Y.-Z., Liu, Y., Xiao, Y., Hu, X., Jiang, L., Zuo, W.-J., Ma, D., Ding, J., Zhu, X., Zou, J., et al. (2021) · Cell Research · doi:10.1038/s41422-020-0375-9 · Cited by 298
Self-citationSmall Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Liu, J., Liu, Q., Li, Y., Li, Q., Su, F., Yao, H., Su, S., Wang, Q., Jin, L., Wang, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000696 · Cited by 183
Self-citationMa, Y., Wang, J., Li, Q., & Cao, B. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2020.1743873 · Cited by 27
Metadata
- Authors
- Hu, X., Zhang, J., Xu, B., Jiang, Z., Ragaz, J., Tong, Z., Zhang, Q., Wang, X., Feng, J., Pang, D., Fan, M., Li, J., Wang, B., Wang, Z., Zhang, Q., Sun, S., & Liao, C.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2014-03-20
- Volume
- 135
- Issue
- 8
- Pages
- 1961-1969
- ISSN
- 0020-7136 (ISSN-L)
- OpenAlex
- W1816099873
- Cited by
- 264
- References
- 42
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.